“As for startup Pinpoint Therapeutics, it was founded on the discovery that drugs designed to combat the malaria virus may also have promise in fighting cancer—and now its scientists are taking their antiviral know-how and applying it to COVID-19. Pinpoint is developing drugs that inhibit PPT1, a pathway targeted by a class of antimalarial drugs known as chloroquines.”